Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Times cited: 194
Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program.
New England Journal of Medicine.
Times cited: 741